Oral Biopharmaceutics and Absorption Modeling Community

A reminder to everyone that the deadline for Programming Proposals for 2026 AAPS NBC is quickly approaching on Sep 26th.  See the announcement here: NBC - American Association of Pharmaceutical Scientists

As part of the Scientific Programming Committee leading "Track 1: Applying Translational Principles Across the Development Lifecycle" along with @Amritangshu Chakravarty, @Swetha Thiyagarajan, and @Joleen White, we would like to invite you to submit your programming proposals. Some focus areas of particular relevance to this group are:

• organ-on-a-chip and organoid applications
• reverse translation to validate preclinical models
• physiologically based pharmacokinetic (PBPK) models
• building initial exposure/response models
• drug-drug interactions
• changes in peptide development after success of GLP-1
• intersection of microbiome and therapeutic effect
• prediction of patient response to different medication options
• recognizing successes in work involving novel modalities

Please reach out with any questions! Looking forward to an amazing conference in San Diego next year

This is a great opportunity. I would love to see programming in this area. Please submit your proposals. Thanks for posting, Babak.

A reminder to everyone that the deadline for Programming Proposals for 2026 AAPS NBC is quickly approaching on Sep 26th.  See the announcement here: NBC - American Association of Pharmaceutical Scientists

As part of the Scientific Programming Committee leading "Track 1: Applying Translational Principles Across the Development Lifecycle" along with @Amritangshu Chakravarty, @Swetha Thiyagarajan, and @Joleen White, we would like to invite you to submit your programming proposals. Some focus areas of particular relevance to this group are:

• organ-on-a-chip and organoid applications
• reverse translation to validate preclinical models
• physiologically based pharmacokinetic (PBPK) models
• building initial exposure/response models
• drug-drug interactions
• changes in peptide development after success of GLP-1
• intersection of microbiome and therapeutic effect
• prediction of patient response to different medication options
• recognizing successes in work involving novel modalities

Please reach out with any questions! Looking forward to an amazing conference in San Diego next year